• Vaccine Name: rMVA-GnGc (Rift Valley fever virus)
• Target Pathogen: Rift Valley Fever virus
• Target Disease: Rift valley fever
• Vaccine Ontology ID: VO_0004663
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• Host Species as Laboratory Animal Model: lambs
• Vector: Modified Vaccinia Ankara (MVA) virus vaccine vector
  • Vector name: Modified Vaccinia Ankara (MVA) virus vaccine vector
  • VO vector ID: VO_0001107
• Preparation: A modified vaccinia virus Ankara (MVA) vectored vaccine encoding the Rift Valley Fever virus (RVFV) glycoproteins Gn and Gc in lambs (Busquets et al., 2014).
• Immunization Route: Intramuscular injection (i.m.)

Sheep Response

• Vaccination Protocol: Three groups of six to seven lambs were immunized as follows: one group received the vaccine (termed rMVA-GnGc), a second group received an MVA vector (vector control) and a third group received saline solution (non-vaccinated control) (Busquets et al., 2014).
• Vaccine Immune Response Type: VO_0000287
• Challenge Protocol: Fourteen days post vaccination, all animals were subcutaneously challenged with 10^5 TCID50 of the virulent RVFV isolate 56/74 and vaccine efficacy assessed using standard endpoints (Busquets et al., 2014).
• Efficacy: The data suggests that a single dose of the rMVA-GnGc vaccine may be sufficient to reduce RVFV shedding and duration of viremia but does not provide sterile immunity nor protection from disease. Further optimization of this vaccine approach in lambs is warranted (Busquets et al., 2014).